NEW
YORK--(BUSINESS WIRE)--Pluristem Therapeutics
Inc. (Nasdaq:PSTI
-
News)(DAX:PJT), a bio-therapeutics company
dedicated to the commercialization of
unrelated donor-patient (allogeneic) cell therapy products for a variety of degenerative, ischemic
and autoimmune indications, announces that
William R. Prather RPh, MD, Sr. VP Corporate
Development, will present at the Fourth Annual
Noble Financial Equity Conference at 12:30 p.m.
(Pacific) on Tuesday, August 19, 2008 at the
Loews Lake Las Vegas Resort, Nevada.
Dr. Prather will give a presentation
regarding Pluristem Therapeutics’
market positioning, clinical trials update,
financial performance, and strategic direction.
The presentation will be webcast LIVE featuring
high-definition, streaming video and PowerPoint
slides. Access is available by logging on to the
conference website
www.noblemadmax.com or by going to the
company’s website at
www.pluristem.com/calendar1.asp. It is
recommended that interested parties register at
least 15 minutes prior to the start of the
presentation to ensure timely access.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a bio-therapeutics
company dedicated to the commercialization of
unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe
degenerative, ischemic and autoimmune disorders.
The Company is developing a pipeline of products,
stored ready-to-use, that are derived from human
placenta, a non-controversial, non-embryonic,
adult stem cell source.
These placental mesenchymal stromal cells
(MSCs) are expanded in the Company's proprietary
PluriXTM 3D bioreactor,
which imitates the natural microstructure of
bone marrow and does not require supplemental
growth factors or other exogenous materials.
Pluristem believes that the resultant PLX
(PLacental eXpanded) cells are multi-potent and
able to differentiate into a variety of cell
types. Recent evidence also suggests their
efficacy may be related to the secretion of
cytokines or other potent immune modulators.
Furthermore, PLX cells are immune privileged and
have immunomodulatory properties, thus
protecting the recipient from immunological
reactions that often accompany transplantations.
Pluristem's first product in development,
PLX-PAD, is intended to improve the quality of
life of millions of people suffering from
peripheral artery disease (PAD). The Company's
products in development also include PLX-BMT,
targeting the global shortfall of matched tissue
for bone marrow transplantation (BMT) by
improving the engraftment of hematopoietic stem
cells (HSCs) contained in umbilical cord blood;
PLX-STROKE, targeting ischemic stroke; PLX-MS,
targeting Multiple Sclerosis; and PLX-IBD,
targeting Inflammatory Bowel Disease (IBD),
which includes Crohn’s
disease and Ulcerative Colitis.
Pluristem has offices in the USA with
research and manufacturing facilities in Israel.
See our product animation on YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us
About Noble Financial
Noble Financial is a privately-held, full-service
capital markets firm driven by what is often
overlooked by other firms - uncovering the value
embedded in the orphaned, undiscovered or
misunderstood company. The company focuses on
converting market inefficiencies into profit
opportunities. Noble Financial supports emerging
companies through strategic advice, investment
banking, market-making, sales & trading,
comprehensive equity research, and the
development of institutional support. Noble
Financial’s equity
conferences – 2008
marks their fourth annual - allow for a unique
blend of professional and personal interaction
among a diverse cross-section of executives. The
company has operated for 24 years and has
offices in Florida, New York City and Boston.
Safe Harbor Statement
This press release may contain forward-looking
statements within the meaning of the "safe
harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and federal
securities laws. These forward-looking
statements are based on the current expectations
of the management of Pluristem only, and are
subject to a number of factors and uncertainties
that could cause actual results to differ
materially from those described in the forward-looking
statements. The following factors, among others,
could cause actual results to differ materially
from those described in the forward-looking
statements: changes in technology and market
requirements; our technology may not be
validated as we progress further and our methods
may not be accepted by the scientific community;
we may be unable to retain or attract key
employees whose knowledge is essential to the
development of our products; unforeseen
scientific difficulties may develop with our
process; results in the laboratory may not
translate to equally good results in real
surgical settings; our patents may not be
sufficient; our products may harm recipients;
changes in legislation; inability to timely
develop and introduce new technologies, products
and applications; loss of market share and
pressure on pricing resulting from competition,
which could cause the actual results or
performance of Pluristem to differ materially
from those contemplated in such forward-looking
statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly
release any revisions to these forward-looking
statements to reflect events or circumstances
after the date hereof or to reflect the
occurrence of unanticipated events. For a more
detailed description of the risk and
uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to
time with the Securities and Exchange Commission.
